Zsolt Harsanyi - EMERGENT BIOSOLUT Independent Director
| ER4 Stock | EUR 9.54 0.09 0.95% |
Director
Dr. Zsolt Harsanyi, Ph.D., is an Independent Director of the Company. Dr. Harsanyi has served as chairman of the board of NGene Research Laboratories, Inc., a privatelyheld biopharmaceutical company, since March 2011. Prior to that, Dr. Harsanyi served as chief executive officer and chairman of the board of directors of Exponential Biotherapies Inc., a private biotechnology company, from December 2004 to February 2011. In January 2016, Dr. Harsanyi returned to Exponential Biotherapies Inc. to serve as chairman of the board. Since August 2016, Dr. Harsanyi was a director of Aptevo Therapeutics Inc., a publiclytraded biotech company which focuses on bringing novel oncology and hematology therapeutics to market. Dr. Harsanyi served as president of Porton International plc, a pharmaceutical and vaccine company, from January 1983 to December 2004. Dr. Harsanyi was a founder of Dynport Vaccine Company LLC in September 1996. Prior to joining Porton International, Dr. Harsanyi was vice president of corporate finance at E.F. Hutton, Inc. Previously, Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress Office of Technology Assessment, served as a consultant to the President Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell Medical College since 2004.
| Age | 75 |
| Tenure | 20 years |
| Professional Marks | Ph.D |
Zsolt Harsanyi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Zsolt Harsanyi against EMERGENT BIOSOLUT stock is an integral part of due diligence when investing in EMERGENT BIOSOLUT. Zsolt Harsanyi insider activity provides valuable insight into whether EMERGENT BIOSOLUT is net buyers or sellers over its current business cycle. Note, EMERGENT BIOSOLUT insiders must abide by specific rules, including filing SEC forms every time they buy or sell EMERGENT BIOSOLUT'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Zsolt Harsanyi over six months ago Acquisition by Zsolt Harsanyi of 25748 shares of Emergent Biosolutions at 5.02 subject to Rule 16b-3 |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
| Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Marvin White, Director | ||
| Kathryn Zoon, Independent Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Independent Director | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.